ARTICLE | Clinical News

Advate octocog alfa: Interim Postmarketing study data

March 10, 2014 7:00 AM UTC

Interim 1-year data from 115 evaluable patients the 4-year, international AHEAD long-term outcomes study showed that median annual bleeding rate was 1.1 in patients receiving prophylactic treatment with Advate (n=85) and 11.8 in patients receiving Advate on demand (n=30). Additionally, 55.3% of prophylactic patients had an annual bleeding rate was 0-2, of which 51% experienced 0 bleeds. Treatment-related adverse events included low titer inhibitors and hypersensitivity. The trial has enrolled 562 patients of a planned 850 patients with hemophilia A to receive Advate in on-demand and prophylaxis regimens for 4 years. Data were presented at the European Association for Haemophilia and Allied Disorders meeting in Brussels. ...